Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Mobile App for Opioid Addiction to Support Patient Detoxification

XTALKS VITALS NEWS

App

To help support patients undergoing opioid detoxification, researchers at Boston University School of Public Health are developing a multifunctional smartphone app.

Share this!

February 8, 2017 | by Sarah Hand, M.Sc.

While drugs like buprenorphine are very effective at helping to treat opioid addiction, some patients can become dependent on their prescribed treatment, making it difficult for them to ever fully stop using the medication. To help support patients undergoing opioid detoxification, researchers at Boston University School of Public Health are developing a multifunctional smartphone app.

Approximately 1.5 million Americans seek help for their opioid addictions each year, some of whom enroll in a treatment program to overcome heroin or prescription opioid abuse. While treatment options can help these patients discontinue opioid use, few resources exist for those in recovery who wish to come off buprenorphine and other opioid alternatives.

The National Institutes of Health (NIH) recently awarded Dr. Michael Stein, of the Health Law, Policy & Management department at Boston University, and his colleagues at the Worcester Polytechnic Institute (WPI), a $414,000 grant to help develop the app. To help patients manage their detoxification symptoms, the app – named OFFBup – will provide educational and self-monitoring tools.



Patients who have been taking buprenorphine or methadone for long periods of time may benefit from the app’s detoxification timeline, which explains the symptoms of withdrawal and when they can occur. The app’s tracking tool could also keep patients motivated by allowing them to see their progress in the detoxification process.

The research team plans to work with patients who are discontinuing buprenorphine use to develop the app within the first year of the NIH’s two-year grant. Their goal is to get the app into the hands of patients at Butler Hospital in Providence, Rhode Island, in the second year of the project.

According to Stein, the app will be “a resource that patients can access anytime and anywhere. Buprenorphine is an effective treatment, but at a certain point—either out of personal preference, because they no longer want to take a medication, or necessity, because they can't afford it—treatment comes to an end. Because we know there are significant side effects to stopping buprenorphine, we think OFFBup will help people get through these and remain drug-free.”


Keywords: App, Opioids, Addiction


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News


FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News


Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Technology Solutions for Late Phase Research: Optimising Real World Data Assets


Serialization for Late Starters – With Live Industry Research Results


Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse


The New Gold Standards of IRT Delivery for Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.